NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 19 June 2025

**Location:** Hybrid Via Manchester Offices and Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair) Present for all items
2. Professor Iolo Doull (Vice Chair) Present for all items
3. Carrie Gardner Present for all items
4. Tina Garvey Present for all items
5. Professor Jonathan Ives Present for all items
6. Professor Dusko Ilic Present for all items
7. Dr Natalia Kunst Present for all items
8. Stuart Mealing Present for all items
9. Sara Payne Present for all items
10. Angharad Shambler Present for all items

NICE staff (key players) present

Ian Watson, Associate Director Present for all items

Greg O'Toole, Project Manager Present for all items

Alan Moore, Health Technology Assessment Adviser Present for all items

Aamer Jawed, Health Technology Assessment Analyst Present for all items

External assessment group representatives present

Sam Bryning, Liverpool Reviews and Implementation Group Items 1.1 to 4.1.3

James Mahon, Liverpool Reviews and Implementation Group Items 1.1 to 4.1.3

Clinical, Patient & NHS England experts present

Professor Alistair Greystroke, Professor of Oncology, nominated by British Thoracic Oncology Group Apologies

Doctor Elizabeth Toy, Consultant Clinical Oncologist, nominated by AstraZeneca Items 1.1 to 4.1.3

Gini Harrison, Research Trustee and Consultant Clinical Oncologist, nominated by AstraZeneca Items 1.1 to 4.1.3

Nina (Shanta) Kale, Regional ambassador London area, nominated by EGFR + UK Items 1.1 to 4.1.3

Peter Clark, CDF expert, NHS England Items 1.1 to 4.1.3

Observers present

Paul Caulfield, Layperson TAC D Present for all items

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Paul Arundel, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Annette Blochberger, Dr Shehla Mohammed, Emtiyaz Chowdhury, and Professor Ed Wilson

### News and announcements

* 1. The chair noted that this is Peter Clark, NHSE, last NICE committee meeting. The chair thanked Peter for his contributions to numerous appraisals over the years.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 22 May 2025.

### Appraisal of Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, here.
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Dusko Ilic, Dr Natalia Kunst, and Professor Johnathan Ives.
  2. Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Topic selection | Project documents | Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223] | Guidance | NICE](https://www.nice.org.uk/guidance/gid-ta11232/documents/html-content)

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Thursday 10 July 2025 and will start promptly at 9am.